A Nature Medicine analysis of 12,000-plus DECLARE-TIMI 58 participants found dapagliflozin reduced heart-failure hospitalization far more in 121 adults carrying rare cardiomyopathy-linked variants than in non-carriers.
Among carriers without prior heart failure, 12.8% in the placebo group developed heart failure over a median 4.2 years, while no events were seen in carriers taking dapagliflozin.
Placebo-treated carriers also faced about eight times the hospitalization risk of non-carriers, suggesting inherited genetics may identify a subgroup with especially large preventive benefit from SGLT2 inhibitors.
Researchers and outside cardiologists called the findings encouraging but hypothesis-generating, noting the small number of variant carriers means dedicated trials are still needed before practice changes.
If confirmed, the results could push cardiology toward earlier genetic screening and pre-symptom treatment for people at inherited risk of cardiomyopathy and heart failure.
With cheap generics approved, should we screen everyone's DNA to find and treat future heart failure patients now?
A diabetes drug can stop genetic heart failure. Will insurers pay to prevent a disease you don't have yet?
80% Reduction in Heart Failure Hospitalization for Cardiomyopathy Variant Carriers: Precision Prevention with Dapagliflozin
Overview
A major genetic substudy of the DECLARE-TIMI 58 trial, published in June 2026, revealed that dapagliflozin dramatically reduces the risk of heart failure hospitalization in people with type 2 diabetes who carry rare cardiomyopathy genetic variants. Out of 17,160 participants, 1,000 with these high-risk variants saw an 80-82% reduction in heart failure hospitalizations when treated with dapagliflozin, compared to only a 32% reduction in non-carriers. This landmark finding highlights the powerful, targeted benefit of dapagliflozin for genetically vulnerable patients and marks a significant step forward in precision medicine for heart failure prevention.